CORMEDIX INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | $0 | $65.4K | $190.9K | $239.2K | $283.3K | $429.8K |
| Product Revenue | — | — | $0 | — | — | — | — | — |
| Cost of Revenue | $22.1M | $3.0M | — | $3.7K | $148.9K | $204.8K | $373.2K | $396.8K |
| Gross Profit | $275.7M | $40.3M | — | $61.7K | $42.0K | $34.4K | $-90.0K | $33.0K |
| Gross Margin | 88.5% | 92.7% | — | 94.3% | 22.0% | 14.4% | -31.8% | 7.7% |
| Operating Expenses | ||||||||
| Research & Development | $19.3M | $3.9M | $13.2M | $10.7M | $13.1M | $13.4M | $11.1M | $18.8M |
| SG&A Expense | $68.2M | $30.0M | $35.8M | $20.0M | $16.3M | $13.9M | $9.9M | $8.1M |
| Operating Income | $150.1M | $-22.4M | $-49.0M | $-30.6M | $-29.4M | $-27.2M | $-21.0M | $-26.9M |
| Operating Margin | 48.2% | -51.4% | — | -46,819.9% | -15,417.5% | -11,378.4% | -7,416.3% | -6,250.4% |
| Interest Expense | — | — | $34.3K | $26.5K | $15.9K | $33.2K | $787.5K | $1.9K |
| Pretax Income | $150.0M | $-19.3M | $-46.3M | $-30.3M | $-29.5M | $-27.2M | $-21.5M | $-26.8M |
| Income Tax Expense | $-13.0M | $-1.4M | — | $-585.6K | $-1.3M | $-5.2M | $-5.1M | — |
| Net Income | $163.1M | $-17.9M | $-46.3M | $-29.7M | $-28.2M | $-22.0M | $-16.4M | $-26.8M |
| Net Margin | 52.3% | -41.2% | — | -45,409.9% | -14,774.7% | -9,207.7% | -5,801.3% | -6,242.4% |
| EPS (Basic) | $2.25 | $-0.30 | $-0.91 | $-0.74 | $-0.75 | $-0.77 | $-1.80 | $-1.51 |
| EPS (Diluted) | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 | $-0.77 | $-1.80 | $-1.51 |
| Shares Outstanding (Basic) | 72.0K | 58.9M | 50.9M | 40.3M | 37.7M | 33.6M | 25.7M | 21.8M |
| Shares Outstanding (Diluted) | 80.3K | 58.9M | 50.9M | 40.3M | 37.7M | 33.6M | 25.7M | 21.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |